Hospital Universitario 12 De Octubre

At Hospital Universitario 12 De Octubre in Madrid, a large share of the research portfolio focuses on oncology, especially advanced and metastatic solid tumors. Studies are designed to test new treatment approaches and compare them with current standards to improve disease control and survival.

• Breast cancer, non-small cell lung cancer, and colorectal cancer
• Ovarian, gastric, pancreatic, and urothelial cancers
• Evaluation of newer targeted and immune-based therapies

Research here also includes biomarker-focused work aimed at matching therapies more precisely to tumor biology.

This site runs extensive studies in blood cancers, covering both newly diagnosed and relapsed disease. The emphasis is on finding better treatment combinations, improving response rates, and supporting longer-lasting remission.

• Leukemia, including acute and chronic forms
• Lymphoma, including diffuse large B-cell, follicular, mantle cell, and Hodgkin lymphoma
• Multiple myeloma and related plasma cell disorders

These trials often compare established regimens with newer options to refine care for patients with difficult-to-treat hematologic disease.

Breast cancer is one of the strongest research areas at Hospital Universitario 12 De Octubre, with studies spanning early-stage, locally advanced, and metastatic disease. The main goal is to improve treatment effectiveness while better tailoring therapy to tumor subtype and molecular features.

• HER2-positive, HER2-negative, and hormone receptor-positive breast cancer
• Triple-negative and endocrine-resistant disease
• Trials exploring targeted therapy, immunotherapy, and combination treatment strategies

Several studies also focus on reducing recurrence risk and improving outcomes after standard therapy.

Another major research field is thoracic oncology, with strong activity in non-small cell lung cancer and small cell lung cancer. The trials aim to improve survival, overcome resistance, and expand options for both untreated and previously treated patients.

• Advanced, metastatic, and locally advanced lung cancer
• Studies in mutation-defined disease such as EGFR, ALK, ROS1, and KRAS alterations
• Testing targeted agents, immune-based treatments, and new combinations

The site’s lung cancer portfolio reflects a strong interest in precision medicine and more effective treatment sequencing.

Research in genitourinary cancers is broad, covering renal cell carcinoma, urothelial carcinoma, and prostate cancer. The studies are focused on improving treatment response in advanced disease and identifying better options after prior therapy.

• Metastatic and unresectable kidney and bladder cancers
• Metastatic castration-resistant and castration-sensitive prostate cancer
• Testing targeted therapies, immunotherapy, and combination regimens

These trials aim to extend disease control and support more personalized treatment choices for patients with difficult genitourinary cancers.

The site also conducts substantial research in gastrointestinal oncology and related liver conditions. Trials are investigating better ways to treat tumors of the digestive system while also addressing selected liver diseases and transplant-related issues.

• Colorectal, gastric, pancreatic, esophageal, and biliary tract cancers
• Hepatocellular carcinoma and advanced liver-related disease
• Studies of new therapies, supportive care, and treatment effectiveness

This area includes research aimed at improving outcomes for both common and hard-to-treat digestive cancers.

Beyond cancer, Hospital Universitario 12 De Octubre participates in trials for immune-mediated and inflammatory diseases. These studies seek to improve symptom control, reduce flares, and evaluate more effective long-term treatment strategies.

• Inflammatory bowel disease, including Crohn’s disease and ulcerative colitis
• Psoriatic arthritis, lupus, and bullous pemphigoid
• Asthma, atopic dermatitis, and other immune-related conditions

These trials often focus on testing newer therapies that may offer better disease control with improved tolerability.

Neurologic research at the site includes both common and rare conditions, with studies aimed at slowing progression, improving function, and easing symptoms. The portfolio spans degenerative, inflammatory, and developmental disorders.

• Alzheimer’s disease and Parkinson’s disease
• Epilepsy, glioma, and other brain tumors
• Rare neurologic and metabolic conditions such as cerebral adrenoleukodystrophy and Niemann-Pick disease

These studies are intended to improve diagnosis, symptom management, and long-term patient outcomes in challenging neurologic disorders.